Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript

PresentationAlexander Siedler Hello. Good morning and good afternoon, everybody, and welcome to our investor webinar on the results of the OCEANIC-STROKE Phase III trial directly live from ISC 2026 in New Orleans. So my name is Alex Siedler. I'm with the Bayer Investor Relations Department, and I'm joined by 3 fine young men with me today. So very much looking forward to being with you for the next hour. And the gentlemen are Christoph Koenen, our Head of Clinical Development and Operations at Bayer. He wil ...